Funding
The NEXUS trial is funded by the Advanced Research and Development Programs for Medical Innovation of Japan Agency for Medical Research and Development (21lk0201148h0001). Encorafenib and binimetinib were provided by ONO PHARMACEUTICAL CO., LTD., and cetuximab was provided by Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945). The funding bodies do not affect the design of the study, data collection, data analysis, interpretation of data, and writing the manuscript.